Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ) and Neurocrine (NBIX). Johnson & Johnson ...

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Neurocrine (NBIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL), Neurocrine (NBIX) and I...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, from Jefferies maintained a Buy rating on Neurocrine, with a price target of $172.00. In addition to Jefferies, Neurocr...

Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX) and Centene (CNC). Neurocrine (NBIX) Wedbush an...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Centene (CNC)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY) and Neurocrine (NBIX). O...

Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (ONCY) and Neurocrine (NBIX)

The latest announcement is out from Neurocrine ( ($NBIX) ). On April 5, 2026, Neurocrine agreed to acquire Soleno Therapeutics via a cash tender of...

Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio

Shares in Soleno Therapeutics ($SLNO) zoomed 28% higher in pre-market trading on reports that it could be bought for $2.5 billion by peer Neurocrin...

Current Quarter	$1.26	Next Quarter	$1.56
Current Year	$6.16	Next Year	$6.96
QoQ Growth	+23.8%	YoY Growth	+13.0%
3Y EPS CAGR	+53.0%	Target Price	$176.59
Consensus	Buy	Upside	+34.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NBIX	$131.64	0.00%	820.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NBIX	$131.64	0%	820.23K
3
4
5
6

NBIX

NBIX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Neurocrine Biosciences Inc. Data in Excel

Get Neurocrine Biosciences Inc. Data in Excel